Your browser doesn't support javascript.
loading
Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
He, Rui; Yuan, Xing; Chen, Zeran; Zheng, Yongfeng.
Afiliación
  • He R; Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan, China.
  • Yuan X; Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan, China.
  • Chen Z; Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan, China.
  • Zheng Y; Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan, China. Electronic address: zyf730@126.com.
Int Immunopharmacol ; 113(Pt B): 109444, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36402069
Metastatic triple negative breast cancer is not only the worst prognosis and the strongest invasive subtype of breast cancer, but also the most immunogenic subtype, so it can be reasonably predicted that immunotherapy can play a positive role in the treatment of metastatic triple negative breast cancer. However, the effect of using PD-1/PD-L1 immune checkpoint inhibitors alone is not very ideal. In recent years, the regimen of combined therapy has been emerging. This article reviews the application of combined immunotherapy based on PD-1/PD-L1 inhibitors in metastatic triple negative breast cancer, including chemotherapy, targeted therapy, radiotherapy and oncolytic virus therapy. The problems existing in combined therapy and the possibility of future research are discussed, which can provide a reference for the selection of treatment options for patients with metastatic triple negative breast cancer in different situations.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígeno B7-H1 / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígeno B7-H1 / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Países Bajos